Artificial intelligence is increasingly making decisions about organ transplants, from identifying donors to predicting which organs will function well after surgery, but medical experts warn that technical accuracy alone isn't enough to justify using these systems in life-or-death situations. A new framework called the GRAFT Checklist is designed to assess whether AI systems in transplantation can be trusted across their entire clinical lifecycle, addressing concerns about bias, transparency, and accountability in a field where over 160,000 patients are waiting for organs and at least 13 people die each day while on the transplant waitlist.

Why Does Transplantation Need Special AI Ethics Rules?

Transplantation is fundamentally different from other medical fields where AI is being deployed. The stakes are existential: decisions made by algorithms directly affect access to life-saving treatment for critically ill patients, graft function after surgery, and patient survival. Beyond the clinical urgency, organ allocation involves complex workflows spanning organ procurement coordinators, surgeons, pathologists, social workers, and pharmacists. Public trust in the entire donation and allocation system depends on people believing the process is fair and transparent.

This context of persistent organ scarcity creates a unique ethical challenge. Traditional AI evaluations focus on performance metrics like accuracy and discrimination, but these measures don't answer the fundamental question transplant teams need answered: should we actually trust this algorithm to help make decisions about who gets an organ? An algorithm might demonstrate excellent predictive performance while remaining opaque, difficult to interpret, vulnerable to bias, or inadequately tested across diverse patient populations.

What Specific Problems Are AI Systems Solving in Transplantation?

AI applications are spreading across the entire transplant continuum, from the moment a potential donor enters the intensive care unit to long-term post-transplant care. In donor identification, AI-based electronic health record screening can identify potential organ donors and predict donor eligibility. Some single-center studies have reported that automated referral triggers increased donor identification by up to 92 percent, though high false-positive rates risk overwhelming ICU workflows and creating over-reliance on algorithms.

Beyond identifying donors, AI is being used to assess organ quality and predict outcomes. In kidney transplantation, machine learning models predict delayed graft function using donor and recipient characteristics, tissue samples, procurement variables, and machine-perfusion parameters. For liver assessment, deep-learning analysis of donor tissue samples and machine learning evaluation of procurement photographs can quantify fat content in organs compared with visual assessment alone. For donor hearts, machine learning models incorporating donor clinical and imaging data have predicted organ acceptance, while AI has been evaluated for donor-lung screening.

During ex vivo perfusion, a technique where organs are kept functioning outside the body before transplant, AI applications integrate real-time metabolic and blood pressure monitoring. By analyzing continuous perfusate trends, AI-based machine perfusion analysis may allow for individualized graft management and improve organ viability.

How to Build Trust in Transplant AI Systems

• Transparency Requirements: AI systems must be explainable to clinicians and patients, not operating as "black boxes" where no one can understand how the algorithm reached its recommendation or decision.
• Bias Assessment: Algorithms must be tested across diverse patient populations to ensure they don't systematically disadvantage certain groups, particularly vulnerable populations already facing barriers to transplantation.
• Human Oversight: Clinical decision-support systems should enhance human judgment rather than replace it, with clear protocols for when clinicians can override algorithmic recommendations.
• Validation Across Settings: AI models trained on data from one hospital system must be rigorously tested before deployment in different clinical environments where patient populations and practices may differ.
• Uncertainty Quantification: Systems should communicate how confident they are in their predictions, acknowledging that machine learning models inherently carry uncertainty, especially in novel situations.

The GRAFT Checklist, integrated with an Understand-Transform-Sustain framework, provides a systematic approach to evaluating AI systems across their clinical lifecycle. Rather than asking "what can this AI do," the framework shifts the conversation to "when and why should we trust this AI".

Clinicians have historically hesitated to adopt recommendations from opaque AI models, and patients and families may question decisions lacking adequate transparency or human oversight. More broadly, public confidence in organ donation could be undermined if AI-driven processes are perceived as inequitable or unfair. The challenge is particularly acute in transplantation because the field depends on voluntary donation and public trust in the integrity of the allocation system.

The emergence of transplant-specific frameworks for responsible AI adoption represents a shift in how the medical community approaches algorithmic decision-making in high-stakes environments. Rather than waiting for regulatory mandates or legal disasters, transplant specialists are proactively developing ethical guidelines that balance the promise of AI to improve organ utilization and patient outcomes with the need for transparency, fairness, and accountability in a field where every decision can mean the difference between life and death.